SK Bioscience Shares Surge After Acquisition Plan
By Kwanwoo Jun
SK Bioscience shares surged as traders cheered the company's plan to acquire a German contract-manufacturing organization.
Shares of the South Korean vaccine developer rose as much as 20% to 59,200 won ($42.46) in early Thursday trading, on course for their sharpest daily percentage gain in nearly two years. The benchmark Kospi was down 0.8%.
SK Bioscience said earlier Thursday that its board decided to buy a controlling 60% stake in IDT Biologika, a member of German pharmaceutical conglomerate Klocke Group, for about KRW339.00 billion.
SK Bioscience values IDT Biologika, one of the top 10 global vaccine contract manufacturers, at KRW656.00 billion.
The South Korean company said it will secure managerial rights to run IDT Biologika after the stake purchase, but will still cooperate with Klocke, which will retain a 40% stake in the German contract manufacturer.
Separately, Klocke will invest KRW76.00 billion to buy a 1.9% stake in SK Bioscience.
"The cross-equity acquisition of the two companies is intended to build a close partnership based on trust in business performance and growth potential," SK Bioscience said in a statement.
SK Bioscience expects the deal to double its revenue, secure advanced manufacturing capabilities and expand its client base in Europe and the U.S.
Write to Kwanwoo Jun at kwanwoo.jun@wsj.com
(END) Dow Jones Newswires
June 26, 2024 22:27 ET (02:27 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Q3 2024 Stock Market Outlook: Is the AI Stock Trade Over?
-
Ian Bremmer: 4 Big Geopolitical Risks to Watch
-
What’s Happening In the Markets This Week
-
Obesity Drug Stocks: Why It Will Be ‘Exceptionally Difficult’ to Dethrone Eli Lilly and Novo Nordisk
-
What Does Chipotle’s Stock Split Mean for Investors?
-
5 Stocks to Buy Before the Fed Cuts Interest Rates in 2024
-
Markets Brief: Inflation Is Back In the Spotlight
-
What a Strong Economy Now Means for the Rest of 2024
-
10 Top Dividend Stocks for 2024
-
Finding Small-Cap Stock Opportunities In a Big-Cap World
-
The 10 Best Companies to Invest in Now
-
Nike Earnings: Dim Sales Outlook Slams Shares, but Patient Investors Could Be Rewarded
-
2 Top E-Commerce Stock Picks
-
Our Top Pick for Investing in US Renewable Energy
-
Micron Earnings: We Raise Our DRAM Forecast and Valuation Behind Stronger Pricing Assumptions
-
10 Undervalued Wide-Moat Stocks